Ozempic Shortage in South Africa 2026: What's Happening and What to Do

If you or someone in your family relies on Ozempic, Wegovy, or another GLP-1 medication and has recently struggled to find stock at your usual pharmacy, you are not imagining it. Intermittent shortages of semaglutide and related medications have continued into 2026, affecting South African patients using these drugs for both type 2 diabetes management and weight loss. Here is an honest look at why this keeps happening, what SAHPRA's role actually is, and -- most importantly -- what you should do if you cannot get your prescription filled.

What Is SAHPRA's Role in Medicine Shortages?

The South African Health Products Regulatory Authority (SAHPRA) is the body responsible for registering and regulating medicines in South Africa, including approving which GLP-1 products may be sold and for which indications. SAHPRA does not manufacture medicines and cannot force a global pharmaceutical company to produce more of a drug -- but it does play an important role in monitoring reported shortages, working with manufacturers and importers on supply timelines, and, where necessary, approving alternative pack sizes, temporary import permits, or Section 21 access to help ease access during a shortfall.

Patients and pharmacists can report shortages and suspected counterfeit or unregistered products directly to SAHPRA, which helps the regulator build an accurate picture of where the pressure points are in the local supply chain.

Why Do GLP-1 Shortages Keep Happening?

The shortages affecting South Africa are part of a global pattern, not a uniquely local problem. Several factors are driving it:

• Explosive global demand. Semaglutide and tirzepatide are used for both type 2 diabetes and weight management, and demand for weight loss use in particular has grown far faster than manufacturers anticipated when building production capacity.
• Limited global manufacturing capacity. Producing GLP-1 injectables requires specialised biologic manufacturing facilities that cannot be scaled up quickly -- new production lines can take years to build and certify.
• Smaller markets are allocated stock last. South Africa, while an important market, is smaller than the United States, the United Kingdom, or the European Union, and global manufacturers often prioritise their largest markets when supply is tight.
• Crackdowns on compounding and grey-market products elsewhere. As regulators in the US and Europe have moved to restrict compounded semaglutide, more of that displaced demand shifts back onto official, regulated supply chains, adding further pressure.
• Currency and import logistics. As an importer of these medications, South African supply is also sensitive to Rand exchange rate fluctuations and import/shipping logistics, which can create additional local delays even when global supply improves.

What to Do If Your Pharmacy Is Out of Stock

A stock-out is frustrating, especially mid-treatment, but there are sensible, safe steps to take rather than panicking or turning to unofficial sources:

1. Call ahead before travelling to your pharmacy. Dis-Chem, Clicks, and independent pharmacies can often tell you over the phone whether they have stock, saving you a wasted trip.
2. Check with more than one branch or pharmacy group. Stock levels vary significantly by branch and region, so a shortage at your regular pharmacy does not necessarily mean a shortage everywhere.
3. Ask to be placed on a waiting list. Many pharmacies keep a list and will call you as soon as new stock arrives.
4. Speak to your doctor promptly. Do not simply skip doses indefinitely or wait too long without guidance -- your doctor can advise whether a short gap is manageable for your specific situation, or whether an alternative is needed.
5. Discuss alternative medications. Depending on your treatment goals, your doctor may suggest temporarily switching between semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), or tirzepatide (Mounjaro), where clinically appropriate. See our comparisons of Wegovy vs Saxenda and Wegovy vs Mounjaro for background on how these options differ.
6. Do not turn to unregulated or compounded alternatives out of desperation. This is the single most important point -- see the next section.

Medical Aid Implications During a Shortage

A stock shortage can also complicate the medical aid side of your treatment:

• You should not be charged for medication that could not be dispensed. If your pharmacy cannot fill your script due to a stock shortage, no valid claim should be processed for that transaction.
• Switching medications may require new authorisation. If your doctor prescribes an alternative GLP-1 medication while you wait for your usual product to return to stock, schemes like Discovery, Bonitas, and Momentum may require a fresh pre-authorisation or motivation letter for the substitute, since formularies and chronic medicine benefit rules differ between products.
• Keep records. Ask your pharmacy for written confirmation of a stock-out if you need to explain a treatment gap or a switch to your medical aid or employer.
• Contact your scheme's chronic medication line directly if you are unsure whether an alternative medication will be covered -- this is far faster than assuming and being caught out at the till.

Is the Shortage Getting Better or Worse?

The picture in 2026 is mixed. Manufacturers have continued investing heavily in new production capacity, and some previously constrained products have seen improved availability compared with 2023-2024. At the same time, new indications and rising local demand for weight management use mean South African pharmacies continue to report intermittent, unpredictable stock-outs of specific doses or products rather than a single, resolved shortage. The most reliable approach remains proactive: order early, keep a buffer where your product's shelf life allows, and maintain an open conversation with your prescribing doctor about contingency options.

The Bottom Line

GLP-1 shortages in South Africa are a real, ongoing supply chain challenge rather than a sign that these medications are being withdrawn or are unsafe. The right response is patience paired with proactive planning: check multiple pharmacies, get on a waiting list, talk to your doctor early, and -- above all -- resist the temptation to fill the gap with an unregulated product bought online or through informal channels. SAHPRA approval exists precisely to protect you from the risks that come with unverified medicines, and that protection matters most during exactly the kind of supply pressure South Africa is experiencing now.

Always consult a registered doctor or pharmacist before changing, substituting, or stopping any prescribed medication.